Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (CDF review of TA593) [ID3755]
In development [GID-TA10675] Expected publication date: 17 June 2021
In development [GID-TA10675] Expected publication date: 17 June 2021
In development [GID-TA10644] Expected publication date: 17 March 2021
In development [GID-TA10674] Expected publication date: 17 March 2021
In development [GID-TA10392] Expected publication date: TBC
In development [GID-TA10743] Expected publication date: 17 November 2021
In development [GID-TA10556] Expected publication date: 17 November 2021
In development [GID-TA10520] Expected publication date: 15 September 2021
In development [GID-TA10302] Expected publication date: 27 January 2021
In development [GID-TA10671] Expected publication date: TBC
In development [GID-TA10371] Expected publication date: TBC
In development [GID-TA10455] Expected publication date: 03 February 2021
In development [GID-TA10485] Expected publication date: 23 June 2021
In development [GID-TA10670] Expected publication date: TBC
In development [GID-TA10713] Expected publication date: TBC
In development [GID-TA10551] Expected publication date: 10 February 2021
In development [GID-TA10651] Expected publication date: 02 February 2022
In development [GID-TA10481] Expected publication date: 18 August 2021
In development [GID-TA10541] Expected publication date: 24 February 2021
In development [GID-TA10373] Expected publication date: 21 April 2021
In development [GID-TA10498] Expected publication date: 13 October 2021
In development [GID-TA10661] Expected publication date: 13 October 2021
In development [GID-TA10639] Expected publication date: TBC
In development [GID-TA10606] Expected publication date: 08 June 2022
In development [GID-TA10630] Expected publication date: 23 March 2022
In development [GID-TA10299] Expected publication date: TBC
In development [GID-TA10470] Expected publication date: TBC
In development [GID-TA10626] Expected publication date: 21 July 2021
Evidence-based recommendations on imatinib for treating unresectable and/or metastatic gastrointestinal stromal tumours (GIST/soft tissue sarcoma)
Evidence-based recommendations on HealOzone (ozone-releasing device) for treating tooth decay (occlusal pit/fissure caries/root caries)
Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for the treatment of chronic hepatitis B
Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)
Evidence-based recommendations on ocriplasmin (Jetrea) for treating vitreomacular traction in adults
Evidence-based recommendatrions on alitretinoin (Toctino) for treating severe chronic hand eczema in adults
Evidence-based recommendations on evacizumab (Avastin), soradenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for renal cell carcinoma
Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours (cancer of stomach/digestive system)
Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults
Evidence-based recommendations on inhaled corticosteroids (ICSs) for chronic asthma in children aged under 12
Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults
Evidence-based recommendations on pemetrexed (Alimta) for treating malignant pleural mesothelioma (cancer)
Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults
Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism to treat people on dialysis who have kidney disease
Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer
Evidence-based recommendations on fludarabine (Fludara) monotherapy for the first-line treatment of chronic lymphocytic leukaemia (CLL)
Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir, Symmetrel) and zanamivir (Relenza) to prevent influenza (flu)
Evidence-based recommendations on spinal cord stimulation (SCS) for chronic pain of neuropathic or ischaemic origin in adults
Evidence-based recommendations on structural neuroimaging for treating first-episode psychosis
Evidence-based recommendations on rituximab for treating relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma in adults
Evidence-based recommendations on onhaled corticosteroids for treating chronic asthma in adults and children aged 12 years and over
Evidence-based recommendations on continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnoea/hypopnoea syndrome